Regarding immunopotentiation approaches, in the Phase I clinical trial NCT00066404, adenoviral-mediated IFN-β transfer induced consistent anti-tumour immune responses; however, the rapid production of anti-adenoviral neutralizing antibodies following second dose administration led to minimized target cell transduction and IFN-β production [206]. This evidence concerns the gene IFNB1 and neoplasm.